{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:49:34Z","timestamp":1787971774015,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis Pharma B.V.","award":["Novartis Pharma B.V."],"award-info":[{"award-number":["Novartis Pharma B.V."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07956-6","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:05:10Z","timestamp":1779858310000},"page":"5760-5773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7392-1626","authenticated-orcid":false,"given":"Lotte G.","family":"Zuur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7780-4545","authenticated-orcid":false,"given":"Denise S.","family":"Hoogenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-2409","authenticated-orcid":false,"given":"Esm\u00e9e C. A.","family":"van der Sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3433-0819","authenticated-orcid":false,"given":"Debra","family":"van Asten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem R.N.","family":"van der Voort-van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-2904","authenticated-orcid":false,"given":"Berlinda J.","family":"de Wit - van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1967-8148","authenticated-orcid":false,"given":"Daphne M. V.","family":"de Vries-Huizing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"Arthur J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-8024","authenticated-orcid":false,"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"10231","key":"7956_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"key":"7956_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"7956_CR3","unstructured":"Schaeffer EMC, An Y, Barocas DMPH et al. NCCN Guidelines Version 1.2023 Prostate Cancer. 2022."},{"issue":"6","key":"7956_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","volume":"67","author":"ZS Zumsteg","year":"2015","unstructured":"Zumsteg ZS, Spratt DE, Romesser PB, et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol. 2015;67(6):1009\u201316.","journal-title":"Eur Urol"},{"key":"7956_CR5","doi-asserted-by":"crossref","unstructured":"Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308\u201323.","DOI":"10.1038\/nrclinonc.2014.68"},{"issue":"3","key":"7956_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","volume":"2","author":"ND James","year":"2016","unstructured":"James ND, Spears MR, Clarke NW, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer. JAMA Oncol. 2016;2(3):348\u201357.","journal-title":"JAMA Oncol"},{"key":"7956_CR7","doi-asserted-by":"crossref","unstructured":"Lilleby W, Narrang A, Tafjord G, et al. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiat Oncol. 2015;10:232.","DOI":"10.1186\/s13014-015-0540-3"},{"issue":"10323","key":"7956_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360.","journal-title":"Lancet"},{"issue":"12","key":"7956_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10276","key":"7956_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"key":"7956_CR11","doi-asserted-by":"crossref","unstructured":"van der Sar ECA, Braat AJAT, van der Voort-van Zyp JRN, et al. Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial). BMC Cancer. 2023;23(1):268.","DOI":"10.1186\/s12885-023-10725-5"},{"issue":"17","key":"7956_CR12","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016;22(17):4291\u2013301.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"7956_CR13","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182\u201391.","journal-title":"Clin Cancer Res"},{"key":"7956_CR14","doi-asserted-by":"crossref","unstructured":"Tagawa ST. Final results of a phase I\/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). ASCO Annual Meeting I2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.5074"},{"issue":"9","key":"7956_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, et al. FDA approval summary: Lutetium Lu 177 Vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7956_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, et al. MIRD Pamphlet 26: Joint EANM\/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. J Nucl Med. 2016;57(1):151\u201362.","journal-title":"J Nucl Med"},{"issue":"6","key":"7956_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","volume":"49","author":"K Sjogreen Gleisner","year":"2022","unstructured":"Sjogreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778\u2013809.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7956_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7(1):88.","journal-title":"EJNMMI Res"},{"key":"7956_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1\u20138.","journal-title":"J Clin Epidemiol"},{"key":"7956_CR20","unstructured":"Giesinger J. Establishing thresholds for clinical importance for disease-specific EORTC questionnaire modules Innsbruck: PROspective - Integrating PRO Data in Health Care and Research; [Available from: https:\/\/prospective.i-med.ac.at\/eortc-module-thresholds\/"},{"key":"7956_CR21","doi-asserted-by":"crossref","unstructured":"Ahmadzadehfar HEE, K\u00fcrpig S, Fimmers R, Yordanova A, Schlenkhoff CD, G\u00e4rtner F, Rogenhofer S, Essler M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016;15;7(11):12477\u201388.","DOI":"10.18632\/oncotarget.7245"},{"issue":"6","key":"7956_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597\u2013610.","journal-title":"Lancet Oncol"},{"key":"7956_CR23","doi-asserted-by":"crossref","unstructured":"Kreissl MC, Mario HH, L\u00f6hr FA, Verburg M, Schiller M, Lassmann C, Reiners SS, Samnick, Andreas K, Buck M, Flentje, Reinhart A, Sweeney. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7(99).","DOI":"10.1186\/1748-717X-7-99"},{"issue":"1","key":"7956_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3413\/Nukmed-0510-12-06","volume":"52","author":"FA Verburg","year":"2013","unstructured":"Verburg FA, Sweeney R, Hanscheid H, et al. Patients with recurrent glioblastoma multiforme. Initial experience with p-[(131)I]iodo-L-phenylalanine and external beam radiation therapy. Nuklearmedizin. 2013;52(1):36\u201342.","journal-title":"Nuklearmedizin"},{"issue":"1051","key":"7956_CR25","doi-asserted-by":"publisher","first-page":"20150042","DOI":"10.1259\/bjr.20150042","volume":"88","author":"A Dietrich","year":"2015","unstructured":"Dietrich A, Koi L, Zophel K, et al. Improving external beam radiotherapy by combination with internal irradiation. Br J Radiol. 2015;88(1051):20150042.","journal-title":"Br J Radiol"},{"issue":"11","key":"7956_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","volume":"64","author":"M Grkovski","year":"2023","unstructured":"Grkovski M, O\u2019Donoghue JA, Imber BS, et al. Lesion dosimetry for [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer. J Nucl Med. 2023;64(11):1779\u201387.","journal-title":"J Nucl Med"},{"key":"7956_CR27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270316","author":"A Pepin","year":"2025","unstructured":"Pepin A, Doucette A, Vapiwala N, et al. Safety of the combination of external beam radiotherapy with (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.125.270316.","journal-title":"J Nucl Med"},{"issue":"6","key":"7956_CR28","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/thno.93249","volume":"14","author":"D Arbuznikova","year":"2024","unstructured":"Arbuznikova D, Klotsotyra A, Uhlmann L, et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [(177)Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 2024;14(6):2560\u201372.","journal-title":"Theranostics"},{"issue":"3","key":"7956_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Buteau JP, Jackson P, et al. Administering [(177)Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study. Eur Urol. 2024;85(3):217\u201326.","journal-title":"Eur Urol"},{"issue":"1","key":"7956_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-023-00952-z","volume":"13","author":"SMB Peters","year":"2023","unstructured":"Peters SMB, Mink MCT, Prive BM, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. EJNMMI Res. 2023;13(1):6.","journal-title":"EJNMMI Res"},{"issue":"10","key":"7956_CR31","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2967\/jnumed.125.270170","volume":"66","author":"M Grkovski","year":"2025","unstructured":"Grkovski M, Krebs SS, O\u2019Donoghue JA, et al. Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2025;66(10):1622\u201330.","journal-title":"J Nucl Med"},{"key":"7956_CR32","unstructured":"Agency EM. Assessment report: Pluvicto. International non-proprietary name: lutetium (177Lu) vipivotide tetraxetan. Procedure No. EMEA\/H\/C\/005483\/0000 .\u00a02022."},{"issue":"9","key":"7956_CR33","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2967\/jnumed.124.269378","volume":"66","author":"J Tran-Gia","year":"2025","unstructured":"Tran-Gia J, Cicone F, Koole M, et al. Rethinking dosimetry: a European perspective. J Nucl Med. 2025;66(9):1323\u201330.","journal-title":"J Nucl Med"},{"key":"7956_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9020013","author":"JL Kalina","year":"2017","unstructured":"Kalina JL, Neilson DS, Comber AP, et al. Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy. Cancers (Basel). 2017. https:\/\/doi.org\/10.3390\/cancers9020013.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7956_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7956_CR36","doi-asserted-by":"crossref","unstructured":"Wright GL Jr, Haley GB, Grossman C, Newhall K, Petrylak K, Troyer D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326\u201334.","DOI":"10.1016\/S0090-4295(96)00184-7"},{"issue":"4","key":"7956_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","volume":"27","author":"BM Priv\u00e9","year":"2026","unstructured":"Priv\u00e9 BM, Noordzij W, Muselaers CHJ, et al. [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol. 2026;27(4):461\u20139.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07956-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:10:30Z","timestamp":1785521430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7956"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07956-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the institutional ethics committee and uploaded at the clinical trial registry (NCT05162573). All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethical approval and consent<b>ual participation<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparing of this manuscript, the authors used Microsoft Copilot and ChatGPT to improve spelling, grammar, readability, and sentence structure. The authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Declaration of ai-assisted writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WVV: has received an unrestricted research grant from Novartis.\u00a0AJATB: is consultant for Boston Scientific, Telix Pharmaceuticals, GE Healthcare and receives research support from Boston Scientific, Telix Pharmaceuticals, GE Healthcare, Ariceum Therapeutics and Siemens Healthineers.\u00a0MGEHL: has acted as a consultant for Boston Scientific and receives research support from Novartis and Boston Scientific.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}